if a copied ReCell only needs an 510k approval then the costs are very moderate for any large pharma. But I don't know if it's only a 510k approval required.
PNV's BTM is a good example.
Patent extension, page-40
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.54 |
Change
0.010(0.40%) |
Mkt cap ! $172.9M | |||
| Open | High | Low | Value | Volume |
| $2.50 | $2.59 | $2.45 | $2.027M | 801.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38052 | $2.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.55 | 5251 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| AVH (ASX) Chart |